Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies

The role of omega-3 polyunsaturated fatty acids (omega-3 or n-3 PUFAs) in the pathogenesis and treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD) is unclear. A systematic review followed by meta-analysis was conducted on: (1) randomized controlled trials (RCTs...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychopharmacology (New York, N.Y.) N.Y.), 2018-02, Vol.43 (3), p.534-545
Main Authors: Chang, Jane Pei-Chen, Su, Kuan-Pin, Mondelli, Valeria, Pariante, Carmine M
Format: Article
Language:English
Subjects:
Adolescent
Adolescents
Attention Deficit Disorder with Hyperactivity - diet therapy
Attention Deficit Disorder with Hyperactivity - metabolism
Attention deficit hyperactivity disorder
Child
Children
Children & youth
Clinical trials
Cognitive ability
Fatty acids
Fatty Acids, Omega-3 - administration & dosage
Fatty Acids, Omega-3 - metabolism
Humans
Meta-analysis
Original
Polyunsaturated fatty acids
Randomization
Randomized Controlled Trials as Topic
Supplements
Systematic review
Teenagers
Tissues
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The role of omega-3 polyunsaturated fatty acids (omega-3 or n-3 PUFAs) in the pathogenesis and treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD) is unclear. A systematic review followed by meta-analysis was conducted on: (1) randomized controlled trials (RCTs) assessing the effects of n-3 PUFAs on clinical symptoms and cognition in children and adolescent with ADHD; and (2) case-control studies assessing the levels of n-3 PUFAs in blood and buccal tissues of children and adolescents with ADHD. In seven RCTs, totalling n=534 randomized youth with ADHD, n-3 PUFAs supplementation improves ADHD clinical symptom scores (g=0.38, p
ISSN:0893-133X
1740-634X
DOI:10.1038/npp.2017.160